{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-030297","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2024-10-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.310663+00:00","generated_at":"2026-05-30T23:11:17.293398+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aytu BioPharma signs exclusive agreement with Lupin to commercialize Adzenys XR-ODT and Cotempla XR-ODT in Canada","bullets":["Exclusive collaboration, distribution and supply agreement with Lupin Pharma Canada for Aytu's ADHD products.","Adzenys XR-ODT and Cotempla XR-ODT are the only extended-release orally disintegrating ADHD tablets; Health Canada approval needed.","Aytu's ADHD prescriptions grew 16.5% over two years; Canadian stimulant market was $1.1B CAD (4.5M units) in 2023.","Lupin will seek regulatory approvals over 18-24 months; financial terms not disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-030297","json":"https://secwatch.observer/filing/0001437749-24-030297.json","markdown":"https://secwatch.observer/filing/0001437749-24-030297.md","text":"https://secwatch.observer/filing/0001437749-24-030297.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000143774924030297/0001437749-24-030297-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000143774924030297/aytu20240723_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T23:11:17.293398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}